However, more recently, a pilot report from a phase I trial of CD123-CAR-T cells in 12 relapsed/refractory AML patients (NCT03766126) showed that only 25% achieved a clinical response [67] (Table 2). This evidence concerns the gene IL3RA and acute myeloid leukemia.